help button home button Am J Pathol International Conference on Pathology of Chest Diseases
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Order Full text via Infotrieve
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brain, S. D.
Right arrow Articles by Williams, T. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brain, S. D.
Right arrow Articles by Williams, T. J.

American Journal of Pathology, Vol 136, 487-490, Copyright © 1990 by American Society for Investigative Pathology

REGULAR ARTICLES

The demonstration of vasodilator activity of pancreatic amylin amide in the rabbit

SD Brain, S Wimalawansa, I MacIntyre and TJ Williams
Department of Applied Pharmacology, National Heart and Lung Institute, London, United Kingdom.

Amylin amide, a 37-amino acid peptide that is a major component of amyloid deposits in the diabetic pancreas, possesses vasodilator activity. Human synthetic amylin amide (30 to 300 pmol/site) stimulated a dose-dependent increase in blood flow after intradermal injection in rabbit skin. Amylin amide was 100 times less active than the structurally related potent vasodilator neuropeptide calcitonin gene- related peptide. Amylin amide did not induce edema formation; however, as a consequence of its vasodilator activity, amylin amide potentiated edema formation induced in rabbit skin by bradykinin. The intravenous injection of amylin amide (10 nmol) caused a systemic drop in blood pressure. This study demonstrates that amylin amide elicits vasodilator responses in vivo. It is possible that the release of amylin amide from the pancreas in type II diabetes could lead to changes in vascular tone.


This article has been cited by other articles:


Home page
 J. Clin. Endocrinol. Metab.Home page
R. L. Hull, G. T. Westermark, P. Westermark, and S. E. Kahn
Islet Amyloid: A Critical Entity in the Pathogenesis of Type 2 Diabetes
J. Clin. Endocrinol. Metab., August 1, 2004; 89(8): 3629 - 3643.
[Abstract] [Full Text] [PDF]

Home page
 Physiol. Rev.Home page
S. D. Brain and A. D. Grant
Vascular Actions of Calcitonin Gene-Related Peptide and Adrenomedullin
Physiol Rev, July 1, 2004; 84(3): 903 - 934.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Endocrinol. Metab.Home page
H. Mulder, S. Gebre-Medhin, C. Betsholtz, F. Sundler, and B. Ahren
Islet amyloid polypeptide (amylin)-deficient mice develop a more severe form of alloxan-induced diabetes
Am J Physiol Endocrinol Metab, April 1, 2000; 278(4): E684 - E691.
[Abstract] [Full Text] [PDF]

Home page
 EndocrinologyHome page
K. J. Perry, M. Quiza, D. E. Myers, M. Morfis, G. Christopoulos, and P. M. Sexton
Characterization of Amylin and Calcitonin Receptor Binding in the Mouse {alpha}-Thyroid-Stimulating Hormone Thyrotroph Cell Line
Endocrinology, August 1, 1997; 138(8): 3486 - 3496.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1990 by the American Society for Investigative Pathology.